Xenon Pharmaceuticals Inc (XENE)
42.48
+1.83
(+4.50%)
USD |
NASDAQ |
May 01, 16:00
42.51
+0.03
(+0.07%)
After-Hours: 20:00
Xenon Pharmaceuticals Revenue (Quarterly)
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
September 30, 2022 | 0.132M |
June 30, 2022 | 0.536M |
March 31, 2022 | 8.766M |
December 31, 2021 | 3.737M |
September 30, 2021 | 8.124M |
June 30, 2021 | 2.218M |
March 31, 2021 | 4.358M |
December 31, 2020 | 5.15M |
September 30, 2020 | 6.554M |
June 30, 2020 | 13.38M |
March 31, 2020 | 7.078M |
December 31, 2019 | 3.329M |
September 30, 2019 | 3.50M |
June 30, 2019 | |
March 31, 2019 | |
December 31, 2018 | |
September 30, 2018 | |
June 30, 2018 | |
March 31, 2018 |
Date | Value |
---|---|
December 31, 2017 | 0.016M |
September 30, 2017 | 0.264M |
June 30, 2017 | 0.015M |
March 31, 2017 | 0.016M |
December 31, 2016 | 0.376M |
September 30, 2016 | 0.413M |
June 30, 2016 | 0.413M |
March 31, 2016 | 0.601M |
December 31, 2015 | 3.227M |
September 30, 2015 | 4.294M |
June 30, 2015 | 4.046M |
March 31, 2015 | 4.01M |
December 31, 2014 | 4.878M |
September 30, 2014 | 13.19M |
June 30, 2014 | 5.298M |
March 31, 2014 | 5.001M |
December 31, 2013 | 5.583M |
September 30, 2013 | 10.79M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.132M
Minimum
Sep 2022
13.38M
Maximum
Jun 2020
5.144M
Average
4.358M
Median
Mar 2021
Revenue (Quarterly) Benchmarks
Acasti Pharma Inc | -- |
Aurinia Pharmaceuticals Inc | 45.10M |
Edesa Biotech Inc | -- |
Lexaria Bioscience Corp | 0.145M |
ESSA Pharma Inc | -- |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -44.74M |
Total Expenses (Quarterly) | 53.70M |
EPS Diluted (Quarterly) | -0.64 |
Enterprise Value | 2.568B |
Earnings Yield | -6.40% |
Normalized Earnings Yield | -4.282 |